U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07807488) titled 'Bioequivalence Study of Rivaroxaban 2.5 mg Tablets Under Fasting and Fed Conditions' on Sept. 02.
Brief Summary: This completed study compared how the body absorbed a single 2.5 mg dose of a test rivaroxaban tablet and the reference product (Xarelto) in healthy adults. The comparison was conducted separately under fasting and fed conditions. The study also evaluated the safety and tolerability of both products.
Study Start Date: March 16, 2022
Study Type: INTERVENTIONAL
Condition:
Healthy Participants
Intervention:
DRUG: Rivaroxaban 2.5 mg Test Tablet
One 2.5 mg rivaroxaban tablet manufactured by Qilu Pharmaceutical Co., Ltd....